242587 ⎘
Non-hormonal steroid modulators of NF-kB for treatment of disease
#2Non-hormonal steroid modulators of NF-kB for treatment of disease
#3Concentrated therapeutic phospholipid compositions
#4Non-hormonal steroid modulators of NF-kB for treatment of disease
#5Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications
#6Concentrated therapeutic phospholipid compositions
#7Compositions and methods using pomegranate extracts
#8Product and process for liquefaction of mucus or sputum
#9Concentrated therapeutic phospholipid compositions
#10Methods of treatment with elastase
#11Method of treating ischemic injury with follistatin-like 1 polypeptide
#12Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications
#13Compositions and methods using pomegranate extracts
#14Inhibiting GS-FDH to Modulate No Bioactivity
#15NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
#16Non-hormonal steroid modulators of NF-κB for treatment of disease
#17METHOD FOR TREATING ATHEROSCLEROSIS OR RESTENOSIS USING MICROTUBULE STABILIZING AGENT
#18Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications
#19Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications
#20Method for treating a mammal by administration of a compound having the ability to release CO
#21METHOD FOR TREATING ATHEROSCLEROSIS OR RESTENOSIS USING MICROTUBULE STABILIZING AGENT
#22Methods of prolonging patency of hemodialysis access
#23Concentrated therapeutic phospholipid compositions
#24Combination therapy for treating hypercholesterolemia
#25Method of treating ischemic injury with follistatin-like 1 polypeptide
#26Methods of using pomegranate extracts for causing regression in lesions due to arteriosclerosis in humans
#27METHOD FOR TREATING ATHEROSCLEROSIS OR RESTENOSIS USING MICROTUBULE STABILIZING AGENT
#28Non-hormonal steroid modulators of NF-κB for treatment of disease
#29Inhibiting GS-FDH to modulate no bioactivity
#30Methods of identifying a subject having or at risk of having or developing coronary artery disease
#31PRODUCT AND PROCESS FOR LIQUEFACTION OF MUCUS OR SPUTUM
#32USE OF A PHOSPHATE ADSORBENT TO COMBAT VASCULAR DISEASES
#33Methods for enlarging the lumen of an obstructed biological conduit
#34Methods for enlarging the diameter of a biological conduit in a human subject
#35Medical agent for preventing or treating diseases resulting from one of inflammation and remodeling, and method for preventing or treating the diseases
#36Compounds and Methods for the Inhibition of the Expression of VCAM-1
#37Method for treating atherosclerosis or restenosis using microtubule stabilizing agent
#382-ethyl and 2-ethylidene-19-nor-vitamin D compounds
#39Product and process for liquefaction of mucus or sputum
#40Cationic liposome delivery of taxanes to angiogenic blood vessels
#41Sustained-release oral molsidomine composition for treating atherosclerosis
#42Combinations of Cholesterol Ester Transfer Protein Inhibitors and HMG COA Reductase Inhibitors for Cardiovascular Indications
#43Poly(diallylamine)-based bile acid sequestrants
#44Process for producing a therapeutically effective amount of an extract from pomegranate and compositions relating to same
#45Method of inhibiting restenosis using bisphosphonates
#46ABCA1 stabilizer
#47Method for treating atherosclerosis or restenosis using microtubule stabilizing agent
#48Inhibiting GS-FDH to modulate no bioactivity
#49Method for inhibiting AGE complex formation
#50Method for inhibiting accelerated atherosclerosis in a subject suffering from hypercholesterolemia or hypertriglyceridemia
#512-ethyl and 2-ethylidene-19-nor-vitamin D compounds
#52Diagnosis and management of infection caused by Chlamydia
#53Phospholipid transfer protein (PLTP) and cholesterol metabolism
#54Method for treating a mammal by administration of a compound having the ability to release CO
#55Nanoparticulate bisphosphonate compositions
#56Method of treating high plasma cholesterol levels
#57Vanadium compounds as anti-angiogenic agents
#58Estrogenic compounds as anti-mitotic agents
#59Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
#60Polyherbal preparation for the prevention of atherosclerosis and hyperlipidemia
#61Method of treating atherosclerosis or restenosis using microtube stabilizing agent
#62Coenzyme Q compositions persisting in blood
#63Methods for treating hypertension in a subject using pomegranate extracts
#64Method for treating insulin resistance, abdominal obesity, hypertension, hyperinsulinemia, and elevated blood lipids with a cortisol inhibitor
#652-ethyl and 2-ethylidene-19-nor-vitamin D compounds
#66Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds
#67Cationic liposome delivery of taxanes to angiogenic blood vessels
#68Mucolytic and anti-elastase compounds and methods of use thereof
#69Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
#70Use of EPA and DHA in secondary prevention
#71Diagnosis and management of infection caused by Chlamydia
#72Synergistic composition for treating hyperilipdemia
#73Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
#74Compounds and methods for the inhibition of the expression of VCAM-1
#75Preventives and/or remedies for hyperphosphatemia
#76Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
#77Therapeutic composition providing enhanced cardiac function
#782-Ethyl and 2-ethylidene-19-nor-vitamin D compounds
#79Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds